Drug Profile
Research programme: cannabinoid-based microencapsulated cell therapies - PharmaCyte Biotech
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Nuvilex
- Developer PharmaCyte Biotech; University of Northern Colorado
- Class Cannabinoids; Cell therapies
- Mechanism of Action Cannabinoid receptor modulators; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain cancer; Cancer; Pancreatic cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Brain-cancer in USA (Parenteral)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (Parenteral)
- 28 Jan 2019 No recent reports of development identified for research development in Cancer in USA (Parenteral)